Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Core Viewpoint - Atara Biotherapeutics, Inc. has announced a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a price of $0.55 per share, aiming to raise approximately $15 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable upon issuance [1]. - The offering is expected to close on or about January 10, 2024, subject to customary closing conditions [1][2]. - The securities are being offered under a shelf registration statement previously filed with the SEC, which was declared effective on November 13, 2023 [2]. Group 2: Company Overview - Atara Biotherapeutics is focused on T-cell immunotherapy, utilizing its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for cancer and autoimmune diseases [1][4]. - The company is recognized for being the first to receive regulatory approval for an allogeneic T-cell immunotherapy, highlighting its innovative approach in the field [4]. - Atara's EBV T-cell platform does not require T-cell receptor or HLA gene editing, allowing for a diverse portfolio of investigational therapies targeting EBV and next-generation AlloCAR-Ts [4].